Proficio Capital Partners LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Proficio Capital Partners LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 64,217 shares of the biotechnology company’s stock, valued at approximately $22,658,000. Proficio Capital Partners LLC owned approximately 0.14% of United Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Milestone Asset Management LLC increased its holdings in shares of United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 1,037 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in shares of United Therapeutics by 9.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after buying an additional 789 shares during the period. JPMorgan Chase & Co. raised its position in shares of United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after acquiring an additional 50,291 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after acquiring an additional 123,929 shares during the period. Finally, Burney Co. boosted its holdings in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after acquiring an additional 12,705 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several recent research reports. UBS Group boosted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,164 shares of company stock worth $45,278,893. Company insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 1.1 %

Shares of United Therapeutics stock opened at $319.96 on Friday. The stock’s fifty day simple moving average is $359.65 and its 200 day simple moving average is $360.71. The company has a market capitalization of $14.28 billion, a PE ratio of 14.05, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same quarter last year, the firm posted $4.36 earnings per share. Analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.